DE69725881D1 - Verfahren zur expression von heterologen proteinen in hefe - Google Patents

Verfahren zur expression von heterologen proteinen in hefe

Info

Publication number
DE69725881D1
DE69725881D1 DE69725881T DE69725881T DE69725881D1 DE 69725881 D1 DE69725881 D1 DE 69725881D1 DE 69725881 T DE69725881 T DE 69725881T DE 69725881 T DE69725881 T DE 69725881T DE 69725881 D1 DE69725881 D1 DE 69725881D1
Authority
DE
Germany
Prior art keywords
isoforms
proteins
pdgf
clipped
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69725881T
Other languages
English (en)
Other versions
DE69725881T2 (de
Inventor
Patricia Tekamp-Olson
P Merryweather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69725881D1 publication Critical patent/DE69725881D1/de
Application granted granted Critical
Publication of DE69725881T2 publication Critical patent/DE69725881T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
DE69725881T 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe Expired - Lifetime DE69725881T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3272096P 1996-12-13 1996-12-13
US32720P 1996-12-13
PCT/US1997/022647 WO1998026080A1 (en) 1996-12-13 1997-12-12 Method for expression of heterologous proteins in yeast

Publications (2)

Publication Number Publication Date
DE69725881D1 true DE69725881D1 (de) 2003-12-11
DE69725881T2 DE69725881T2 (de) 2004-09-09

Family

ID=21866458

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69738768T Expired - Lifetime DE69738768D1 (de) 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen
DE69739319T Expired - Lifetime DE69739319D1 (de) 1996-12-13 1997-12-12 Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe
DE69725881T Expired - Lifetime DE69725881T2 (de) 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69738768T Expired - Lifetime DE69738768D1 (de) 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen
DE69739319T Expired - Lifetime DE69739319D1 (de) 1996-12-13 1997-12-12 Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe

Country Status (9)

Country Link
US (10) US6083910A (de)
EP (4) EP0948538B1 (de)
JP (4) JP4275741B2 (de)
AT (3) ATE426030T1 (de)
AU (2) AU5794598A (de)
DE (3) DE69738768D1 (de)
ES (1) ES2306462T3 (de)
PT (1) PT948538E (de)
WO (2) WO1998025963A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123228B1 (de) 1983-04-25 1993-09-29 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
JP4275741B2 (ja) * 1996-12-13 2009-06-10 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 血小板由来増殖因子タンパク質の分析および分離
DE69922978T2 (de) * 1998-10-06 2005-12-08 Emalfarb, Mark Aaron, Jupiter Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
WO2005011619A2 (en) * 2003-01-31 2005-02-10 Five Prime Therapeutics, Inc. Lung-expressed polypeptides
JP2007529993A (ja) 2003-07-02 2007-11-01 シンジェンタ パーティシペーションズ アーゲー グルカナーゼ、それらをコードする核酸並びにそれらを製造及び使用する方法
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
JP5236189B2 (ja) 2003-12-05 2013-07-17 チルドレンズ ホスピタル メディカル センター オリゴ糖組成物および感染症の治療における該組成物の使用
GB2429207A (en) * 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
JP2008503217A (ja) * 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
BRPI0512396A (pt) * 2004-07-21 2008-03-11 Ambrx Inc polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
US7799754B2 (en) * 2004-10-14 2010-09-21 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
CN101087875B (zh) * 2004-12-22 2012-08-22 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
MX2007007587A (es) 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
SG158149A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
CA2615057A1 (en) * 2005-07-12 2007-01-18 Codon Devices, Inc. Compositions and methods for biocatalytic engineering
CN101273140B (zh) 2005-08-18 2013-01-16 Ambrx公司 tRNA组合物和其用途
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
CN104710503B (zh) * 2005-11-08 2023-04-25 Ambrx 公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
NZ571113A (en) * 2005-11-17 2012-02-24 Biomimetic Therapeutics Inc Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
CA2882445A1 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
ES2664229T3 (es) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador
KR20090052360A (ko) 2006-09-08 2009-05-25 암브룩스, 인코포레이티드 척추동물 세포에서의 서프레서 ｔＲＮＡ 전사
CA2662753C (en) * 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
EP2615108B1 (de) 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
CA2668189C (en) 2006-11-03 2016-01-26 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures comprising a solution of platelet derived growth factor (pdgf) incorporated in a biocompatible matrix
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
KR20160121601A (ko) 2007-03-30 2016-10-19 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
EP2076533B1 (de) 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
CA2736661A1 (en) * 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
AU2009212151C1 (en) 2008-02-07 2015-09-17 Biomimetic Therapeutics, Llc Compositions and methods for distraction osteogenesis
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
BR122020000059B8 (pt) 2008-09-09 2021-06-22 Biomimetic Therapeutics Inc composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
NZ601659A (en) 2008-09-26 2014-02-28 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
EA201170493A1 (ru) 2008-09-26 2011-10-31 Амбркс, Инк. Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2011087810A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
WO2011103598A1 (en) 2010-02-22 2011-08-25 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
RS65223B1 (sr) 2010-08-17 2024-03-29 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN105085652B (zh) 2014-05-16 2021-06-22 中国人民解放军军事医学科学院生物工程研究所 血小板衍生生长因子b突变体、其制备方法及用途
JP6871855B2 (ja) * 2014-10-14 2021-05-19 サムエル リンチ， 創傷を処置するための組成物
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业（上海）股份有限公司 一种用离子交换层析纯化蛋白质的方法
CN108239648B (zh) * 2016-12-26 2023-04-07 丰益(上海)生物技术研发中心有限公司 高效表达米黑根毛霉脂肪酶的方法
TW201837051A (zh) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
WO2020106600A1 (en) * 2018-11-19 2020-05-28 Basf Se Leader sequence for yeast

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359180A (en) * 1942-08-11 1944-09-26 Gen Motors Corp Dynamic balancer
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4889919A (en) * 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US4769328A (en) * 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5187263A (en) * 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
EP0487116B1 (de) * 1984-10-12 1999-12-29 ZymoGenetics, Inc. Von Blutplättchen abstammende biologisch aktive Analoga eines Wachstumsfaktors in eukaryotischen Zellen
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
DE3751632T2 (de) * 1986-08-13 1996-06-13 Zymogenetics Inc Expression von biologisch-aktiven PDGF-Analogen in eukaryotischen Zellen
IE60517B1 (en) 1986-11-14 1994-07-27 Inst Molecular Biology Inc Wound healing and bone regeneration
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5219759A (en) 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5968778A (en) * 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
DE69031218T2 (de) 1990-04-10 1997-12-11 Inst Molecular Biology Inc Wundheilung
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
DE69102651T2 (de) * 1990-07-23 1994-10-06 Zymogenetics Inc Proteaseresistenter pdgf und dessen verwendungen.
ES2061416T3 (es) * 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
WO1993008825A1 (en) 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
CA2154363A1 (en) * 1993-01-22 1994-08-04 Bruce A. Sullenger Localization of therapeutic agents
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
BR9408072A (pt) 1993-11-16 1997-08-12 Depotech Corp Vesículas com liberação controlada de ativos
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
EP0755454B1 (de) * 1994-04-13 2008-02-13 The Rockefeller University Aav-vermittelte überbringung von dna in zellen des nervensystems
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
JP4275741B2 (ja) * 1996-12-13 2009-06-10 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 血小板由来増殖因子タンパク質の分析および分離
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6001311A (en) * 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules

Also Published As

Publication number Publication date
JP2008119008A (ja) 2008-05-29
EP1365028B1 (de) 2009-03-18
JP2001518073A (ja) 2001-10-09
US20060252695A1 (en) 2006-11-09
US20020055169A1 (en) 2002-05-09
EP0948538B1 (de) 2008-06-11
JP2008031173A (ja) 2008-02-14
US6312923B1 (en) 2001-11-06
ES2306462T3 (es) 2008-11-01
ATE253120T1 (de) 2003-11-15
US6897043B2 (en) 2005-05-24
US7166446B2 (en) 2007-01-23
PT948538E (pt) 2008-08-05
US6083910A (en) 2000-07-04
US20030036511A1 (en) 2003-02-20
DE69739319D1 (de) 2009-04-30
EP1935901A1 (de) 2008-06-25
ATE426030T1 (de) 2009-04-15
WO1998026080A1 (en) 1998-06-18
US6017731A (en) 2000-01-25
US6448382B1 (en) 2002-09-10
JP4275741B2 (ja) 2009-06-10
AU5794598A (en) 1998-07-03
US6706496B2 (en) 2004-03-16
US6083723A (en) 2000-07-04
EP0946736A1 (de) 1999-10-06
JP2001506497A (ja) 2001-05-22
DE69738768D1 (de) 2008-07-24
US7084262B2 (en) 2006-08-01
WO1998025963A1 (en) 1998-06-18
ATE398139T1 (de) 2008-07-15
EP0946736B1 (de) 2003-10-29
AU5465498A (en) 1998-07-03
DE69725881T2 (de) 2004-09-09
EP1365028A1 (de) 2003-11-26
EP0948538A1 (de) 1999-10-13
US20030077831A1 (en) 2003-04-24
US20050124042A1 (en) 2005-06-09
JP4341859B2 (ja) 2009-10-14

Similar Documents

Publication Publication Date Title
ATE253120T1 (de) Verfahren zur expression von heterologen proteinen in hefe
RU95115239A (ru) Аналог эритропоэтина
DE69331507T2 (de) Verfahren zur Reinigung von menschlichem, rekombinantem Serumalbumin
ATE187462T1 (de) Reinigung von alpha-l-proteinaseinhibitor mittels neuen chromatographischen trennungsbedingungen
DK0409472T3 (da) Knoglemorfogenetisk protein
IT8547835A0 (it) Procedimento di purificazione di proteine ossee
BR9406716A (pt) Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-10) polipeptideo de proteina-10 morfogenética de osso purificada (BMP-10) e molécula de DNA quimérica
DE173233T1 (de) Methode und mittel fuer chromatografie.
DE3177260D1 (de) Fuer plasminogen-aktivator kodierende rekombinante desoxyribonukleinsaeure und verfahren zur herstellung von plasminogen-aktivator-protein daraus.
NO920671D0 (no) Fremgangsmaate for aktivering av rekombinante proteiner
DE3884356D1 (de) Verfahren zur Herstellung von Fremdprotein in Hefe, Rekombinant DNS, Transformant.
DE69326559T2 (de) Rekombinante methode und wirt zur herstellung von xylitol
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
FI862152A0 (fi) Anordning foer bestaemning av graden av konsistens hos en egenskap foer ett omraode i en diskreta bildelement uppdelad bild.
DE3683512D1 (de) Verfahren zur optischen isomerisierung von optisch aktiver aminosaeure und verfahren zur herstellung von optisch aktiver aminosaeure.
DE59712000D1 (de) Herstellung von Carbonsäurefluoriden
DE3761373D1 (de) Verfahren zur herstellung von fluor enthaltenden alpha,beta-ungesaettigten carbonsaeuren.
ES2193349T3 (es) Metodo para la produccion de rdspa alfa1.
DE68910036T2 (de) Luciferase-Gen und neue rekombinante DNA sowie Verfahren zur Herstellung von Luciferase.
DE69503956T2 (de) Verfahren zur Herstellung von optisch aktiver alpha-(Hydroxyphenoxy)-alkancarbonsäure und ihren Derivaten
NO970081D0 (no) Fremgangsmåte for folding av proteiner som rekombinant hirudin eller epidermisk vekstfaktor
DE69716106D1 (de) Trennung von proteinen durch kapillarelektrophorese mit aminosäure enthaltenden puffern
KR970070017A (ko) 재조합 인 과립구 콜로니 자극인자(rhG-CSF)의 정제방법
DE3688974T2 (de) Expressionssysteme zur überproduktion gewünschter proteine.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US